Paper41520178
IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity.
Barragán Bravo GA and 22 others. Mol Ther, 2026. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity. Papers, record 41520178. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41520178
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Receptors, Chimeric Antigen | Major topic |
| Interleukin-18 | Major topic |
| Immunotherapy, Adoptive | Major topic |
| Natural Killer T-Cells | Major topic |
| Humans | |
| Animals | |
| Mice | |
| Interleukin-15 | |
| Cell Line, Tumor | |
| Metabolic Reprogramming | |
| Cytotoxicity, Immunologic | |
| Xenograft Model Antitumor Assays |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA262250 | NCI NIH HHS | United States | R01CA262250 | PubMed | NIH RePORTER |
| R01 CA247436 | NCI NIH HHS | United States | R01CA247436 | PubMed | NIH RePORTER |
| P50 CA126752 | NCI NIH HHS | United States | P50CA126752 | PubMed | NIH RePORTER |
| P30 CA125123 | NCI NIH HHS | United States | P30CA125123 | PubMed | NIH RePORTER |
| S10 OD028671 | NIH HHS | United States | S10OD028671 | PubMed | NIH RePORTER |
References104
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19637196 | IL-18 skews the invariant NKT-cell population via autoreactive activation in atopic eczema. | Eur J Immunol | 2009 | https://conductscience.org/library/papers/19637196 | PubMed |
| 2 | 22455463 | clusterProfiler: an R package for comparing biological themes among gene clusters. | OMICS | 2012 | https://conductscience.org/library/papers/22455463 | PubMed |
| 3 | 38168996 | IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. | Nat Biotechnol | 2024 | https://conductscience.org/library/papers/38168996 | PubMed |
| 4 | 36520914 | Multidimensional control of therapeutic human cell function with synthetic gene circuits. | Science | 2022 | https://conductscience.org/library/papers/36520914 | PubMed |
| 5 | 27183388 | CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo. | J Clin Invest | 2016 | https://conductscience.org/library/papers/27183388 | PubMed |
| 6 | 40864984 | CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia. | Blood | 2025 | https://conductscience.org/library/papers/40864984 | PubMed |
| 7 | 34376537 | Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming. | Clin Cancer Res | 2021 | https://conductscience.org/library/papers/34376537 | PubMed |
| 8 | 33616889 | Naxitamab: First Approval. | Drugs | 2021 | https://conductscience.org/library/papers/33616889 | PubMed |
| 9 | 27530312 | Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity. | Hum Gene Ther | 2017 | https://conductscience.org/library/papers/27530312 | PubMed |
| 10 | 33499253 | Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/33499253 | PubMed |
| 11 | 24227677 | featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. | Bioinformatics | 2014 | https://conductscience.org/library/papers/24227677 | PubMed |
| 12 | 33428453 | Cytokine Regulation and Function in T Cells. | Annu Rev Immunol | 2021 | https://conductscience.org/library/papers/33428453 | PubMed |
| 13 | 18978797 | Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. | Nat Med | 2008 | https://conductscience.org/library/papers/18978797 | PubMed |
| 14 | 21990318 | Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. | Cancer Res | 2011 | https://conductscience.org/library/papers/21990318 | PubMed |
| 15 | 31863285 | A comprehensive pathway map of IL-18-mediated signalling. | J Cell Commun Signal | 2020 | https://conductscience.org/library/papers/31863285 | PubMed |
| 16 | 36175679 | KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. | Nat Med | 2022 | https://conductscience.org/library/papers/36175679 | PubMed |
| 17 | 30778252 | Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. | Nat Immunol | 2019 | https://conductscience.org/library/papers/30778252 | PubMed |
| 18 | 40604285 | Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery. | Nature | 2025 | https://conductscience.org/library/papers/40604285 | PubMed |
| 19 | 38579288 | IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model. | Blood | 2024 | https://conductscience.org/library/papers/38579288 | PubMed |
| 20 | 36347021 | Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy. | Blood | 2023 | https://conductscience.org/library/papers/36347021 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42183670 | CAR-iNKT cells for cancer therapy: a comprehensive review of engineering, mechanisms, and clinical progress. | Immunotherapy | 2026 | https://conductscience.org/library/papers/42183670 |
Source PubMed
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CASP9 | 842 | PubTator's text mining | https://conductscience.org/library/genes/842 | NCBI Gene |
| IL15 | 3600 | PubTator's text mining | https://conductscience.org/library/genes/3600 | NCBI Gene |
| IL18 | 3606 | PubTator's text mining | https://conductscience.org/library/genes/3606 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41520178
GET https://conductscience.org/api/papers/v1/41520178/authors?page=2